Literature DB >> 22052855

Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model.

Reid Hayward1, Chia-Ying Lien, Brock T Jensen, David S Hydock, Carole M Schneider.   

Abstract

BACKGROUND: Childhood cancer survivors are at greater risk of cardiovascular complications once they reach adulthood. Anthracyclines may be a major contributor to these delayed-onset complications, yet their use continues because of favorable clinical outcomes. Exercise has been shown to protect against anthracycline cardiotoxicity, yet it is unclear whether exercise can protect against delayed-onset cardiotoxicity when treatment is initiated in childhood. The aim of the present study was to determine if exercise training provides cardioprotection in a juvenile rat model of delayed-onset anthracycline cardiotoxicity. PROCEDURE: At 25 days of age, male Sprague-Dawley rat pups were subjected to a treatment regimen with the anthracycline doxorubicin (DOX). Pups received DOX at 2 mg/kg on 7 consecutive days (cumulative dose 14 mg/kg) or saline as a control. At the time DOX treatment began, pups remained sedentary or were allowed to voluntarily exercise. Ten weeks after the initiation of exercise, cardiac function was assessed both in vivo and ex vivo.
RESULTS: DOX treatment stunted normal growth and significantly impaired cardiac function. While voluntary exercise did not offset changes in the growth curve, it did provide significant cardioprotection against DOX-induced cardiotoxicity.
CONCLUSIONS: Exercise training, initiated at the time treatment begins, can protect against delayed-onset anthracycline-induced cardiotoxicity in adult rats that were treated with anthracyclines as juveniles.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22052855     DOI: 10.1002/pbc.23392

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  17 in total

Review 1.  Exercise Training and Cardiovascular Health in Cancer Patients.

Authors:  Ray W Squires; Adam M Shultz; Joerg Herrmann
Journal:  Curr Oncol Rep       Date:  2018-03-10       Impact factor: 5.075

2.  Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.

Authors:  Reid Hayward; David Hydock; Noah Gibson; Stephanie Greufe; Eric Bredahl; Traci Parry
Journal:  J Physiol Biochem       Date:  2012-08-14       Impact factor: 4.158

3.  Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.

Authors:  Nobutoshi Matsumura; Beshay N Zordoky; Ian M Robertson; Shereen M Hamza; Nirmal Parajuli; Carrie-Lynn M Soltys; Donna L Beker; Marianne K Grant; Maria Razzoli; Alessandro Bartolomucci; Jason R B Dyck
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

4.  ST2 as a Biomarker to Show the Preventive Effect of Exercise in Myocardial Injury by Doxorubicin?

Authors:  Jieun Lee; Eung Ju Kim
Journal:  Int J Heart Fail       Date:  2021-03-30

5.  Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity.

Authors:  Fei Wang; Brian Iskra; Eugenie Kleinerman; Claudia Alvarez-Florez; Thomas Andrews; Angela Shaw; Joya Chandra; Keri Schadler; Gregory J Aune
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

6.  Concomitant low-dose doxorubicin treatment and exercise.

Authors:  Kathleen Sturgeon; Keri Schadler; Geetha Muthukumaran; Dennis Ding; Akinyemi Bajulaiye; Nicholas J Thomas; Victor Ferrari; Sandra Ryeom; Joseph R Libonati
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-09       Impact factor: 3.619

Review 7.  Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.

Authors:  Joseph J Chen; Pei-Tzu Wu; Holly R Middlekauff; Kim-Lien Nguyen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-06       Impact factor: 5.125

Review 8.  Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors.

Authors:  Amy A Kirkham; Margot K Davis
Journal:  J Oncol       Date:  2015-08-03       Impact factor: 4.375

9.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

10.  EXercise to prevent AnthrCycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocol.

Authors:  Melanie R Keats; Scott A Grandy; Nicholas Giacomantonio; David MacDonald; Miroslaw Rajda; Tallal Younis
Journal:  Pilot Feasibility Stud       Date:  2016-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.